Journal
ELIFE
Volume 3, Issue -, Pages -Publisher
ELIFE SCIENCES PUBLICATIONS LTD
DOI: 10.7554/eLife.03821
Keywords
-
Categories
Funding
- Wellcome Trust [069598/Z/02/Z]
- Medical Research Council
- National Institute for Health Research Oxford Biomedical Research Centre
- Oxford Martin School
- Frederick National Laboratory for Cancer Research [HHSN261200800001E]
- Intramural Research Program of the NIH, Frederick National Lab, Center for Cancer Research
- MRC [MC_UU_12023/16, G108/626, MR/L006588/1] Funding Source: UKRI
- Medical Research Council [MR/L006588/1, 986404, G108/626] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0513-10093, NF-SI-0507-10313] Funding Source: researchfish
Ask authors/readers for more resources
In HIV-1 infection, a population of latently infected cells facilitates viral persistence despite antiretroviral therapy (ART). With the aim of identifying individuals in whom ART might induce a period of viraemic control on stopping therapy, we hypothesised that quantification of the pool of latently infected cells in primary HIV-1 infection (PHI) would predict clinical progression and viral replication following ART. We measured HIV-1 DNA in a highly characterised randomised population of individuals with PHI. We explored associations between HIV-1 DNA and immunological and virological markers of clinical progression, including viral rebound in those interrupting therapy. In multivariable analyses, HIV-1 DNA was more predictive of disease progression than plasma viral load and, at treatment interruption, predicted time to plasma virus rebound. HIV-1 DNA may help identify individuals who could safely interrupt ART in future HIV-1 eradication trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available